On January 10, 2020 Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, reported that in 2019 it entered into agreements with nine new companies (Press release, Adimab, JAN 10, 2020, View Source [SID1234552992]). In addition, Adimab announced the expansion of 11 of its current partnerships and the achievement of 62 technical and development milestones across numerous collaborations.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Over the past 11 years, Adimab has partnered with over 70 companies for the discovery of therapeutic IgGs and bispecific antibodies, resulting in more than 315 therapeutic programs originating from the Adimab Platform. In 2019, Adimab and its partners added 55 new therapeutic programs. New alliances for 2019 include collaborations with Amagma Therapeutics, Black Belt Therapeutics, BYOMass Inc., Galderma, iOmx Therapeutics, Nextpoint Therapeutics, TRex Bio, and VelosBio. In addition, Adimab expanded its collaborations with Acceleron, Alector, Biotheus, Boehringer Ingelheim, Celgene (now a Bristol-Myers Squibb company), Innovent Biologics, Inc., Novartis, Regeneron, Scholar Rock, Takeda Pharmaceuticals, and others.
In 2019, Adimab also entered into a new Platform Transfer agreement with Takeda Pharmaceuticals.
"We are very happy with the number of new 2019 partnerships," said Guy Van Meter, Chief Business Officer of Adimab. "That said, our most important success metric from a deal perspective is partners coming back for expansions. More than 70% of our current partners, once they have seen our capabilities, have expanded their relationships with us."
"Historically, Adimab has positioned itself as the industry leader for generating the highest quality therapeutic IgGs with exquisite specificity and excellent developability profiles," said Tillman Gerngross, Chief Executive Officer and Co-Founder of Adimab. "We are increasingly expanding into adjacent areas; for example, we are engineering more and more IgGs and non-IgGs derived from other technologies. We are working with many types of bispecific molecules, and our new proprietary CD3 binders have been used in more than ten partnerships."
In the last six years, Adimab has worked with an increasing number of smaller companies backed by leading venture capital firms. Following successful antibody discovery campaigns, many of these companies have gone on to partner their programs with larger pharmaceutical companies. To date, more than 15 programs developed by venture-backed partners have been out-licensed to larger pharma companies. Transactions publicly announced in 2019 include: a Black Belt Therapeutics program out-licensed to CASI Pharmaceuticals, a Dragonfly program out-licensed to Abbvie, Iconic granted an option to Exelixis, Iconic granted an option to Novartis, among others.